About Cabling Installation & Maintenance

Our mission: Bringing practical business and technical intelligence to today's structured cabling professionals

For more than 30 years, Cabling Installation & Maintenance has provided useful, practical information to professionals responsible for the specification, design, installation and management of structured cabling systems serving enterprise, data center and other environments. These professionals are challenged to stay informed of constantly evolving standards, system-design and installation approaches, product and system capabilities, technologies, as well as applications that rely on high-performance structured cabling systems. Our editors synthesize these complex issues into multiple information products. This portfolio of information products provides concrete detail that improves the efficiency of day-to-day operations, and equips cabling professionals with the perspective that enables strategic planning for networks’ optimum long-term performance.

Throughout our annual magazine, weekly email newsletters and 24/7/365 website, Cabling Installation & Maintenance digs into the essential topics our audience focuses on.

  • Design, Installation and Testing: We explain the bottom-up design of cabling systems, from case histories of actual projects to solutions for specific problems or aspects of the design process. We also look at specific installations using a case-history approach to highlight challenging problems, solutions and unique features. Additionally, we examine evolving test-and-measurement technologies and techniques designed to address the standards-governed and practical-use performance requirements of cabling systems.
  • Technology: We evaluate product innovations and technology trends as they impact a particular product class through interviews with manufacturers, installers and users, as well as contributed articles from subject-matter experts.
  • Data Center: Cabling Installation & Maintenance takes an in-depth look at design and installation workmanship issues as well as the unique technology being deployed specifically for data centers.
  • Physical Security: Focusing on the areas in which security and IT—and the infrastructure for both—interlock and overlap, we pay specific attention to Internet Protocol’s influence over the development of security applications.
  • Standards: Tracking the activities of North American and international standards-making organizations, we provide updates on specifications that are in-progress, looking forward to how they will affect cabling-system design and installation. We also produce articles explaining the practical aspects of designing and installing cabling systems in accordance with the specifications of established standards.

Cabling Installation & Maintenance is published by Endeavor Business Media, a division of EndeavorB2B.

Contact Cabling Installation & Maintenance

Editorial

Patrick McLaughlin

Serena Aburahma

Advertising and Sponsorship Sales

Peter Fretty - Vice President, Market Leader

Tim Carli - Business Development Manager

Brayden Hudspeth - Sales Development Representative

Subscriptions and Memberships

Subscribe to our newsletters and manage your subscriptions

Feedback/Problems

Send a message to our general in-box

 

Hummingbird Bioscience Announces Poster Presentation on HMBD-802, Novel Dual-Payload Antibody-Drug Conjugate, at EORTC-NCI-AACR 2024

SAN FRANCISCO and SINGAPORE, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Hummingbird Bioscience, a precision biotherapeutics company discovering and developing transformative biologics for hard-to-treat diseases, today announced a poster presentation on HMBD-802, a novel first-in-class dual-payload anti-HER2 antibody-drug conjugate, at the 36th EORTC-NCI-AACR symposium (23-25 October 2024).

“We are excited to present at EORTC-NCI-AACR with data demonstrating how HMBD-802 can potently treat tumors in T-DXd-insensitive settings whilst maintaining an optimal safety profile. I look forward to sharing more about its potential as a therapeutic option post and beyond T-DXd for HER2-positive cancers,” said Jerome Boyd-Kirkup, PhD, Chief Scientific Officer of Hummingbird Bioscience.

Poster details
Title: A novel HER2 targeted dual-payload ADC, HMBD-802, overcomes resistance to topoisomerase 1 inhibitor ADCs
Date: 24 October 2024
Location: Exhibition Hall
Session: Antibody-drug conjugates
Poster number: PB154
Abstract number: 166

About HMBD-802
HMBD-802 is a novel, first-in-class anti-HER2 dual-payload antibody-drug conjugate developed with Hummingbird Bioscience’s proprietary antibody and dual-payload ADC platform technologies. HMBD-802 allows targeted delivery of payloads to HER2-expressing tumors to maximize anti-tumor efficacy, overcome topoisomerase 1 inhibitor resistance, and reduce systemic toxicity.

About Hummingbird Bioscience

Hummingbird Bioscience is a precision biotherapeutics company discovering and developing transformative biologics for hard-to-treat diseases. To address key challenges with current antibody-drug conjugate (ADC) therapies, Hummingbird Bioscience is building a pipeline of next-generation ADCs using its proprietary antibody discovery and linker/payload platforms. The company has a pipeline of ADCs in preclinical development and other novel biologics including monoclonal antibodies, HMBD-001 (anti-HER3 mAb) and HMBD-002 (anti-VISTA mAb) in Phase I and an out-licensed ADC (HMBD-501) that is slated for the clinic. The Hummingbird Bioscience approach combines computational and systems biology with wet lab drug discovery in a multi-disciplinary, collaborative environment spanning initial discovery through clinical development. The company harnesses this integrated approach across target identification and patient selection, enabling the team to increase the efficiency of translating novel scientific insights while reducing the inherent risk in drug discovery and development. At Hummingbird Bioscience, the commitment to rigorous science, teamwork, and intellectual integrity underpins our passion to accelerate the journey of new drugs from concept to clinic.

For more information, please visit www.hummingbirdbioscience.com, and follow Hummingbird Bioscience on LinkedInX (formerly Twitter), and YouTube.


Contacts

Media:
Crystal Ho
c.ho@hummingbirdbio.com
media@hummingbirdbio.com
+65 6979 5580

Investors:
investors@hummingbirdbio.com

Primary Logo

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.